Trial · NCT04227470
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of treatment related adverse events (AEs) | 189 days | Number of treatment related adverse events (AEs) |
| Secondary | Immunoglobins changes from baseline to week 27 | 189 days | Change of concentration of immunoglobins in mg/ml overtime after administration of HBM9161 from baseline to week 27 |
| Secondary | Neurological Disability changes from baseline to week 27 | 189 days | Neurological Disability changes from baseline to week 27 as measured by Expanded Disability Scale Score (EDSS, Score 0-10, higher means a worse outcome) |
| Secondary | Low Contrast Visual Acuity (LCVA) changes from baseline to week 27 | 189 days | Low Contrast Visual Acuity (LCVA) changes from baseline to week 27 as measured by Sloan Low Contrast Letter Scale (SLCLS Letter, Score 0-70, higher means a better outcome) |
| Secondary | Patient reported improvement changes from baseline to week 27 | 189 days | Patient reported improvement changes from baseline to week 27 as measured by Patient Global Impression-Improvement (PGI-I, Score 1-7, higher means a worse outcome) |
| Secondary | Percentage of patients who received rescue therapy | 189 days | Percentage of patients who received rescue therapy |
| Secondary | Percentage of patients who have relapse | 189 days | Percentage of patients who have relapse |
| Secondary | Walking ability changes from baseline to week 27 | 189 days | Walking ability changes from baseline to week 27 as measured by time used for 25-foot Walk (applicable for patients who are able to walk) |
| Secondary | The seropositive rate of anti-HBM9161 antibody after treatment | 189 days | Evaluation of the seropositive rate of anti-HBM9161 antibody after treatment |
| Other | Maximum change from baseline to week 27 in total serum AQP4-IgG concentrations | 189 days | Maximum change from baseline in total serum AQP4-IgG concentrations |
| Other | AQP4-IgG changes from baseline to week 27 | 189 days | Change of serum concentration of AQP4-IgG overtime after administration of HBM9161 from baseline to week 27 |
| Other | HBsAb level changes from baseline to week 27 | 189 days | Change in HBsAb level overtime after administration of HBM9161 from baseline to week 27 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04227470/registered